Alumis Inc (ALMS)

Currency in USD
26.00
-0.31(-1.18%)
Closed·
26.34+0.34(+1.31%)
·
ALMS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.5226.96
52 wk Range
2.7627.20
Key Statistics
Prev. Close
26
Open
26.21
Day's Range
25.52-26.96
52 wk Range
2.76-27.2
Volume
1.25M
Average Volume (3m)
2.8M
1-Year Change
293.3434%
Book Value / Share
3.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALMS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.25
Upside
+43.27%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Alumis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Alumis Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Compare ALMS to Peers and Sector

Metrics to compare
ALMS
Peers
Sector
Relationship
P/E Ratio
−13.2x−3.7x−0.6x
PEG Ratio
−0.17−0.090.00
Price/Book
8.4x1.7x2.6x
Price / LTM Sales
146.5x16.9x3.4x
Upside (Analyst Target)
38.5%3.4%42.5%
Fair Value Upside
Unlock−4.6%5.0%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 37.25
(+43.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Chardan Capital Markets
Buy37.00+42.31%-New Coverage21/01/2026
H.C. Wainwright
Buy40.00+53.85%20.00Maintain09/01/2026
Morgan Stanley
Buy33.00+26.92%22.00Maintain07/01/2026
Wells Fargo
Buy39.00+50.00%17.00Maintain07/01/2026
Guggenheim
Buy32.00+23.08%18.00Maintain07/01/2026

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-1.06 / --
Revenue / Forecast
2.07M / --
EPS Revisions
Last 90 days

Alumis (ALMS) Income Statement & Profits

People Also Watch

20.07
ZBIO
+3.88%
7.12
ROLR
-2.06%
1.98
ACRV
+2.06%
9.28
KYTX
+4.50%

FAQ

What Is the Alumis (ALMS) Share Price Today?

The live Alumis share price today is 26.00

What Stock Exchange Does Alumis (ALMS) Trade On?

Alumis is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Alumis?

The stock symbol (also called a 'ticker') for Alumis is "ALMS."

What Is the Current Alumis Market Cap?

As of today, Alumis market capitalisation is 3.24B.

What Is Alumis's (ALMS) Earnings Per Share (TTM)?

The Alumis EPS is currently -3.38 (Trailing Twelve Months).

When Is the Next Alumis Earnings Date?

Alumis's next earnings report will be released on 25 Mar 2026.

Is ALMS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Alumis moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alumis Stock Split?

Alumis has split 0 times. (See the ALMS stock split history page for full effective split date and price information.)

How Many Employees Does Alumis Have?

Alumis has 222 employees.

What is the current trading status of Alumis (ALMS)?

As of 28 Jan 2026, Alumis (ALMS) is trading at a price of 26.00, with a previous close of 26.00. The stock has fluctuated within a day range of 25.52 to 26.96, while its 52-week range spans from 2.76 to 27.20.

What Is Alumis (ALMS) Price Target According to Analysts?

The average 12-month price target for Alumis is USD37.25, with a high estimate of USD50 and a low estimate of USD32. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +43.27% Upside potential.

What Is the ALMS After Hours Price?

ALMS's last after hours stock price is 26.34, the stock has decreased by 0.34, or 1.31%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.